Board of Directors

Bellicum’s Board of Directors includes founder Dr. Kevin Slawin, Series A investor representative Frank McGuyer, and CEO Tom Farrell.

• Kevin M. Slawin, MD
  Kevin Slawin is Director, Vanguard Urologic Institute and the Texas Prostate Center; Professor, Center for Clinical and Translational Sciences, UTHSC-Houston; Clinical Professor of Urology, Baylor College of Medicine; and Director of Urology, Memorial Hermann Hospital – TMC. He is a pioneer in the field of robotic surgery, co-inventor of the [-2]proPSA prostate cancer screening test, and a thought leader in the diagnosis and treatment of prostate cancer. As CMO, Dr Slawin has strategic responsibility for the company’s clinical activities.
• Frank B. McGuyer
  Frank McGuyer represents the Series A investors. Mr. McGuyer is Chairman & CEO of McGuyer Homebuilders Inc., one of the largest private builders in Texas and among the 25 largest homebuilders in the nation.
• Thomas J. Farrell
  Thomas Farrell joined Bellicum in February 2006. He has a twelve year track record as a serial life science entrepreneur. Prior to joining Bellicum, he was founding President & CEO of San Diego-based Cylene Pharmaceuticals, a venture-backed company developing a novel class of small molecules as anti-cancer therapy, targeting secondary DNA structures and associated kinases. He received his M.B.A. at Stanford Graduate School of Business, where he was an Arjay Miller Scholar.